Engineering chemokines to develop optimized HIV inhibitors.
about
HIV and the chemokine system: 10 years later.Short-term monotherapy in HIV-infected patients with a virus entry inhibitor against the gp41 fusion peptidePeptide and protein-based inhibitors of HIV-1 co-receptorsCharacterization of the chemokine CXCL11-heparin interaction suggests two different affinities for glycosaminoglycans.Highly potent chimeric inhibitors targeting two steps of HIV cell entryPotent Anti-HIV Chemokine Analogs Direct Post-Endocytic Sorting of CCR5A scalable low-cost cGMP process for clinical grade production of the HIV inhibitor 5P12-RANTES in Pichia pastoris.Highly potent, fully recombinant anti-HIV chemokines: reengineering a low-cost microbicide.Maraviroc in the treatment of HIV infection.Chemokine oligomerization and interactions with receptors and glycosaminoglycans: the role of structural dynamics in functionThe role of biliary epithelial cells in the immunopathogenesis of non-suppurative destructive cholangitis in murine hepatic graft-versus-host disease.Combination of the CCL5-derived peptide R4.0 with different HIV-1 blockers reveals wide target compatibility and synergic cobinding to CCR5The Role of Natural Antibodies to CC Chemokine Receptor 5 in HIV Infection.Rational CCL5 mutagenesis integration in a lactobacilli platform generates extremely potent HIV-1 blockers.An engineered CX3CR1 antagonist endowed with anti-inflammatory activity.
P2860
Q27473020-666A7ACD-9E51-4B3F-9E82-612F92E58BACQ27666404-82EDB104-4763-4FCA-9F9E-285258CA2E6EQ30352117-BAE2D708-2C01-49C1-8B3B-261DF48906E5Q33885243-53FE9834-9E3A-4FCC-9F0B-717124787398Q35150195-EBA09797-124B-45B2-9298-CC81745EB724Q35617641-C914B278-5B6B-4DC7-8D32-DCCF6D13E6C5Q36498554-7AB4B98D-68EB-4634-A24A-7B52E5DEA7EEQ36976659-7D4EBCE6-6028-4529-B03D-3DA6E1619AC7Q37634319-591481B7-4A4E-4C28-BDB6-4968BBC320E9Q37827607-72DB8BD1-429E-41B7-8AD7-BCBE60F17B65Q39757544-24D44D05-4127-4849-9D6A-41D93510CFEEQ41897622-6C279B13-437F-41C7-8914-8B7ED7974D7EQ47107303-D0763B9E-EB82-4CC2-B05B-BA39C5756CB1Q47800411-C22E3FE4-DA85-4C58-9F3E-F34B5830E80DQ51778397-02D60ACF-9B09-4BDC-81B5-B5E714240256
P2860
Engineering chemokines to develop optimized HIV inhibitors.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Engineering chemokines to develop optimized HIV inhibitors.
@ast
Engineering chemokines to develop optimized HIV inhibitors.
@en
type
label
Engineering chemokines to develop optimized HIV inhibitors.
@ast
Engineering chemokines to develop optimized HIV inhibitors.
@en
prefLabel
Engineering chemokines to develop optimized HIV inhibitors.
@ast
Engineering chemokines to develop optimized HIV inhibitors.
@en
P356
P1476
Engineering chemokines to develop optimized HIV inhibitors.
@en
P2093
Oliver Hartley
Robin E Offord
P304
P356
10.2174/1389203054065400
P577
2005-06-01T00:00:00Z